(Total Views: 792)
Posted On: 12/17/2024 1:05:21 PM
Post# of 155128
Robust newsy update from Cytodyn this morning. This one came out of the blue:
“Second, in September, CytoDyn applied to the NIH/RECOVER-TLC group for the potential inclusion of leronlimab in their next round of Long Covid treatment studies. We expect to learn the group’s decision in the next several months.”
I had made a filing for Leronlimab consideration under the NIH’s RECOVER-TLC initiative and listened to the last zoom call to go over the results. Based on their discussion I sent an email to Jeanne Marrazzo who is head of NIAID and among the principals on the call…she thanked me for the information, little did I know Dr Jay was already on the job.
While things tend to move slow in the public health arena, the tone of the presentation was one of sincerity in getting to a treatment(s) that will move the PASC needle. They were clear in their preference for agents/treatments that are “ready to go”, not phase 1. Also, those that can affirm outcomes with biomarkers/measurements that are on a clearer footing compared to (for example) symptom scores. Leronlimab checks those boxes and would be ready for a phase 2b/3. If selected for trial it could put Leronlimab on a trajectory to win the approval race.
“Second, in September, CytoDyn applied to the NIH/RECOVER-TLC group for the potential inclusion of leronlimab in their next round of Long Covid treatment studies. We expect to learn the group’s decision in the next several months.”
I had made a filing for Leronlimab consideration under the NIH’s RECOVER-TLC initiative and listened to the last zoom call to go over the results. Based on their discussion I sent an email to Jeanne Marrazzo who is head of NIAID and among the principals on the call…she thanked me for the information, little did I know Dr Jay was already on the job.
While things tend to move slow in the public health arena, the tone of the presentation was one of sincerity in getting to a treatment(s) that will move the PASC needle. They were clear in their preference for agents/treatments that are “ready to go”, not phase 1. Also, those that can affirm outcomes with biomarkers/measurements that are on a clearer footing compared to (for example) symptom scores. Leronlimab checks those boxes and would be ready for a phase 2b/3. If selected for trial it could put Leronlimab on a trajectory to win the approval race.
(37)
(0)
